Transaction DateRecipientSharesTypePriceValue
3rd February 2021Jennifer Jarrett16,000Grant/award etc.$0.00
1st February 2021Terry J Rosen311,900Bona fide gift$0.00
19th January 2021Jennifer Jarrett400,000Grant/award etc.$0.00
19th January 2021Terry J Rosen45,000Grant/award etc.$0.00
19th January 2021Carolyn C. Tang12,538Grant/award etc.$0.00
19th January 2021Juan C. Jaen19,375Grant/award etc.$0.00
16th December 2020William Grossman2,117Open or private sale$31.35$66,367.95
19th November 2020Kathryn E Falberg795Open or private sale$807.84$642,232.80
19th November 2020Kathryn E Falberg232Open or private sale$806.63$187,138.16
19th November 2020Kathryn E Falberg20,000Conversion of derivative$0.00
Arcus Biosciences
Arcus Biosciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Ticker: RCUS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1724521
Employees: 139
Exchange: New York Stock Exchange
Auditor Opinion:

Disclosure Language changes
Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.
Red Flags
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
Fundamentals
Cash at Carrying Value: $285 M (0%)
Assets, Current: $472 M (144%)
Property, Plant and Equipment, Net: $8 M (-11%)
Other Assets, Noncurrent: $1 M (51%)
Assets: $481 M (137%)
Accounts Payable, Current: $12 M (156%)
Accrued Liabilities, Current: $6 M (0%)
Liabilities, Current: $40 M (76%)
Other Liabilities, Noncurrent: $693 Th (-14%)
Liabilities: $53 M (34%)
Common Stock, Value, Issued: $6 Th (50%)
Common Stock, Shares, Issued: $59 M (28%)
Retained Earnings (Accumulated Deficit): $278 M (35%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $144 Th (125%)
Stockholders' Equity (Parent): $429 M (0%)
Liabilities and Equity: $481 M (137%)
Revenue: $2 M (-50%)
Research and Development: $36 M (-39%)
General and Administrative Expenses: $11 M (-38%)
Operating Income/Loss: $45 M (-38%)
Other Income, net: $301 Th (-68%)
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
News
Generic placeholder
Arcus Biosciences: Highly Valued Even Without A Phase 3 Study

17th January 2021